WO2008093247A2 - Medicament for the treatment of endometriosis - Google Patents
Medicament for the treatment of endometriosis Download PDFInfo
- Publication number
- WO2008093247A2 WO2008093247A2 PCT/IB2008/001273 IB2008001273W WO2008093247A2 WO 2008093247 A2 WO2008093247 A2 WO 2008093247A2 IB 2008001273 W IB2008001273 W IB 2008001273W WO 2008093247 A2 WO2008093247 A2 WO 2008093247A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- endometriosis
- treatment
- dopamine agonist
- use according
- day
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to medicaments for the treatment of endometriosis
- Endometriosis is a benign, chronic, gynaecological disease It may be defined as a presence of endometrial tissue, comprising both glandular epithelium and stroma, outside the uterine cavity It is a benign gynaecological disorder, which, in a sub-population of female patients, may develop into an aggressive disease Endometriosis is associated with various distressing symptoms including dysmenorrhoea, dyspareunia, pelvic pain and reduced fertility
- angiogenesis the process whereby new blood vessels are formed from pre-existing vessels
- vascular permeability factor/vascular endothelial growth factor VP/VEGF
- VP/VEGF vascular permeability factor/vascular endothelial growth factor
- the potential effectiveness of anti-angiogenic therapy for treating endometriosis has been assessed using a study using human endometrial tissues transplanted to immuno-compromised nude mice
- Four different anti-angiogenic agents were administered three weeks after the endometrial explants had been transplanted (Nap et a/, 2004) All four inhibitors were able to reduce the size of established explants, and new blood vessel formation was stopped
- the known anti-angiogenic agents are highly toxic, and rather difficult to introduce in a human clinical setting
- compositions which include a dopamine agonist may be used to treat endometriosis
- the present invention therefore provides the use of a dopamine agonist in the manufacture of a medicament for the treatment and/or prevention of endometriosis
- the present invention also provides the use of a dopamine agonist in the treatment and/or prevention of endometriosis
- treatment of endometriosis includes treatment to reduce (or remove) the amount of endometrial tissue which is present outside the uterine cavity (e g reduction or removal of endometriotic lesions) and/or treatment to reduce and/or ameliorate one or more symptoms associated with endometriosis (e g treatment to ameliorate and/or reduce the symptoms of dysmenorrhoea, treatment to ameliorate and/or reduce the symptoms of dyspareunia, and/or treatment to ameliorate and/or reduce pelvic pain)
- treatment of endometriosis includes treatment to reduce the number of instances, and/or reduce the size of instances, of endometrial tissue which is present outside the uterine cavity (e g reduction of number and/or
- endometriosis includes, for example, peritoneal endometriosis, ovarian endometriosis and deep endometriosis.
- dopamine agonist means a compound that acts like dopamine, for example, a drug which interacts (e g binds specifically) with a dopamine receptor to mimic a dopamine action It does not include compounds which are exclusively "dopaminergic substances", i e exclusively compounds which, through different mechanisms of action, increase the levels of dopamine
- dopamine agonist does not include the bridged indenopyrrolocarbazoles disclosed in US 6359130
- Dopamine agonists have previously been found to be useful in the treatment or prevention of ovarian hyperstimulation syndrome (OHSS) (WO
- Dopamine agonists within the terms of the invention include, but are not limited to, amantadine, bromocryptine, cabergoline, quinagolide, lisunde, pergolide, ropinirole and pramipexole
- a preferred dopamine agonist for use in the present invention is cabergoline.
- a preferred dopamine agonist for use in the present invention is quinagolide
- the so-called "partial dopamine agonists" (e g tergu ⁇ de) may also be used in accordance with the invention However, the use of dopamine agonists is preferred
- a single dopamine agonist is used
- the dopamine agonist may be administered at a dose (e g an oral dose to a human patient) of between 25 micrograms per day and 80 mg/day, preferably between 50 micrograms per day and 5 mg/day, more preferably between 300 micrograms per day and 1 mg/day, suitable doses within this range depend to the dopamine agonist to be used, as is readily apparent to those skilled in the art
- the dopamine agonist is cabergoline
- the cabergoline is administered at a dose (e g an oral dose to a human patient) of between 0 01 and 12 5 mg/week, preferably between 0 1 and 10 mg/week, more preferably between 0 5mg and 5 mg/week, more preferably at a dose of between 3 5 mg/week and 4 mg/week
- the dopamine agonist may be administered as, for example, a single daily dose (of for example, between 0 1 mg/day and 5mg/day, from 0 2 mg/day to 1 mg/day, for example 0 5 mg/day), or the daily dose may be divided into two or more sub-doses to be taken at different times over a 24 hour period
- the dopamine agonist (cabergoline) may be administered as a daily dose at the levels above, or as equivalent doses e g per week, twice a week, or every two days In one regime, the dopamine agonist (for example, cabergoline) is
- the dopamine agonist is quinagolide
- the quinagolide is administered at a dose (e g an oral dose to a human patient) of between 25 and 1000 micrograms/day, preferably between 25 and 500 micrograms/day, more preferably between 25 and 300 micrograms/day
- the dopamine agonist may be administered as, for example, a single daily dose, or the daily dose may be divided into two or more sub-doses to be taken at different times over a 24 hour period
- the dopamine agonist (quinagolide) may be administered as a daily dose at the levels above, or as equivalent doses e g per week, twice a week, or every two days
- the dopamine agonist is bromocryptine
- the bromocryptine is administered at a dose (e g an oral dose to a human patient) of between 10 to 80 micrograms/day, preferably 10 to 40 mg/day
- the dopamine agonist is used as the only medical treatment for endometriosis
- the dopamine agonist may be used in the absence of other medical or surgical treatments [for example, in the absence of danazol]
- administration of a dopamine agonist may be combined with other medical or surgical treatments for endometriosis [for example, NSAIDs and/or hormonal treatments (danazol, OCs, medroxyprogesterone acetate, other progestins, GnRH agonists and antagonists, aromatase inhibitors)]
- other medical or surgical treatments for endometriosis for example, NSAIDs and/or hormonal treatments (danazol, OCs, medroxyprogesterone acetate, other progestins, GnRH agonists and antagonists, aromatase inhibitors)
- surgical treatment or medical treatment may be used prior, during or after treatment with dopamine agonist
- dopamine agonist may provide substantial clinical benefits such as, for example significant decrease in the percentage of active endometriotic lesions, significant loss of the cellularity and organisation manifesting characteristics of atrophic or degenerative tissue in endometriotic lesions, and significant decrease in the number of new blood vessels in endometriotic lesions
- the dopamine agonist for example, cabergoline
- the dopamine agonist may be administered for long periods of time (e g 1 to 3 weeks (e g 1 to 21 days, for example 1 to 14 days), from 1 day to 3 months, 1 day to six months, 1 day to 12 months, or 1 day to 2 years, or longer) with therapeutically beneficial effect, and low risk of side effects
- the administration may be continuous at e g daily or weekly dose, or may be interrupted by one or more interruptions of, for example, a number (e g 1 to 3) of weeks or a number (e g 1 to 3) of months
- the dopamine agonist may be administered for as long as pain (or other symptom) continues
- the dopamine agonist for example, cabergoline, quinagolide
- the dopamine agonist may be administered to a pregnant subject
- the treatment or prevention of endometriosis may be associated with a decrease in the amount of endometrial glands
- vascular endothelial growth factor may be targeted by the dopamine agonist, as a factor in the development of endometriosis
- the isoforms VEGF 121 and VEGF 165 appear to be mainly involved in the process of angiogenesis (Watkins, R H , et al , Am J Physiol 1999, vol 276, pp 858-67)
- Two specific endothelial cell membrane receptors for VEGF have been identified, VEGF rece ⁇ tor-1 (VEGFR-1 , Flt-1) and VEGFR-2 (FIk- 1/KDR)
- VEGFR-2 appears to be mainly involved in regulating angiogenesis and vasculogenesis
- VEGFR-2 (KDR) may thus be targeted by the dopamine agonist, as a factor in the development of endometriosis
- Notch-4 may be targeted by the dopamine agonist, as a factor in the development of endometriosis VEGF
- VEGFR-2 and Notch-4 may be targeted by the dopamine agonist, as a factor in the development of endometriosis
- Other mechanisms of action of the dopamine agonist are within the scope of the invention
- the dopamine agonist is administered as a pharmaceutically acceptable preparation
- Preparations may be administered in accordance with the invention in pharmaceutically acceptable compositions that may optionally comprise pharmaceutically acceptable salts, buffering agents, preservatives and excipients
- Pharmaceutical preparations which include dopamine agon ⁇ st(s) as active agents are well known in the art and are commercially available
- cabergoline is available under the registered trade marks Cabaser and Sogilen/Dostinex
- the use of such commercially available dopamine agonist preparations in the treatment of endometriosis is according to the invention
- the mode of administration selected will depend on the acuteness and severity of the condition being treated, and the dosage required Any mode of administration that produces desired therapeutic effect without unacceptable adverse effects is relevant in practicing the invention
- Such modes of administration may include oral, rectal, topical, transdermal, sublingual, intramuscular, parenteral, intravenous, intracavity, vaginal, and adhesive matrix to be used during surgery
- Various approaches for formulating compositions for use in accordance with the invention are described in the Handbook of Pharmaceutical Excipients, Third Edition, American Pharmaceutical Association, USA and Pharmaceutical Press UK (2000), and Pharmaceutics - The Science of Dosage Form Design, Churchill Livingston (1988)
- the administration is oral Compositions suitable for oral administration include capsules, cachets, tablets, syrups, elixirs or lozenges
- a method of treatment or prevention of endometriosis comprising a step of administration to a patient in need thereof of a dopamine agonist
- the dopamine agonist is administered in the form of a pharmaceutical preparation which includes one or more dopamine agonists as the active ingredient
- the dopamine agonist may be administered at a dose (e g an oral dose to a human patient) of between 25 micrograms per day and 80 mg/day, preferably between 50 micrograms per day and 5 mg/day, more preferably between 300 micrograms per day and 1 mg/day, suitable doses within this range depend to the dopamine agonist to be used, as is readily apparent to those skilled in the art
- the dopamine agonist is cabergoline
- the cabergoline is administered at a dose (e g an oral dose to a human patient) of between 0 01 and 12 5 mg/week, preferably between 0 1 and 10 mg/week, more preferably between 0 5mg and 5 mg/week, more preferably at a dose of between 3 5 mg/week and 4 mg/week
- the dopamine agonist may be administered as, for example, a single daily dose (of for example, between 0 1 mg/day and 5mg/day, from 0 2 mg/day to 1 mg/day, for example
- the dopamine agonist is quinagolide
- the quinagolide is administered at a dose (e g an oral dose to a human patient) of between 25 and 1000 micrograms/day, preferably between 25 and 500 micrograms/day, more preferably between 25 and 300 micrograms/day
- the dopamine agonist may be administered as, for example, a single daily dose, or the daily dose may be divided into two or more sub-doses to be taken at different times over a 24 hour period
- the dopamine agonist (quinagolide) may be administered as a daily dose at the levels above, or as equivalent doses e g per week, twice a week, or every two days
- the dopamine agonist is bromocryptine
- a dose e g an oral dose to a human patient
- a dose e g an oral dose to a human patient
- a dopamine agonist may be combined with other medical or surgical treatments for endometriosis [for example, NSAIDs and/or hormonal treatments (danazol, OCs, medroxyprogesterone acetate, other progestins, GnRH agonists and antagonists, aromatase inhibitors)]
- surgical treatment or medical treatment may be used prior, during or after treatment with dopamine agonist
- the dopamine agonist for example, cabergoline
- the dopamine agonist may be administered for long periods of time (e g 1 to 3 weeks (e g 1 to 21 days, for example 1 to 14 days), from 1 day to 3 months, 1 day to six months, 1 day to 12 months, or 1 day to 2 years, or longer) with therapeutically beneficial effect, and low risk of side effects
- the administration may be continuous at e g daily or weekly dose, or may be interrupted by one or more interruptions of, for example, a number (e g 1 to 3) of weeks or a number (e
- the patient may be pregnant
- the treatment or prevention of endometriosis may be associated with a decrease in the amount of endometrial glands
- FIGURE 1 shows the percentage of active lesions following the animal study discussed below, for the control group, and the groups treated with low dose (0 05 mg/kg/day) and high dose (0 1 mg/kg/day) of cabergoline
- FIGURE 1 a shows the glands/stroma ratio in the three established groups [both low and high cabergoline ("Cb2") doses had more stroma and less glands than the controls ( * P ⁇ 0 05)]
- FIGURE 2 shows the blood vessels (mm 3 ) for the control and low and high dose groups
- FIGURE 3 shows the percentage of “mature” and “newly formed” blood vessels in the animals of the control, low and high dose groups
- FIGURE 4 shows the Proliferation Index for the control and low and high dose groups
- FIGURE 5 shows the relative expression of VEGF, VEGFR-2 (KDR), Notch-4, Ang 1 and Wnt-1 for the control, low and high dose groups
- FIGURE 6a shows the presence of dopamine receptor 2 (Dp-r2) and VEGF in endometrial implants of the animals in the three established groups (control, low and high dose groups)
- FIGURE 6b shows the relative expression of VEGF, VEGFR-2 (KDR) and D2R in endometriotic lesions (left-hand column) and in the endometrium (right- hand column)
- mice Female mice (Hsd Athimic Nude- nu, Harlan lberica S L, Barcelona, Spain) were individually housed in autoclaved cages and bedding, in laminar flow filtered hoods The animal room was maintained at 26 C with a 12-h light, 12-h dark cycle, and mice were fed ad libitum with autoclaved laboratory rodent chow and acidified water All handling was performed in laminar flow filtered hoods
- a mixture of ketamine/medetomidine 75 ⁇ g/g ketamine and 1 ⁇ g/g medetomidine) (Ketolar ® , Parke-Davis, Espa ⁇ a, Domtor®, Pfizer, Spam) i p injected, was used to anesthetize mice before invasive procedures and atipamezole (Antisedan®, SmithKline Beecham, Spain) 1 ⁇ g/g i
- 17 ⁇ -estrad ⁇ ol (Innovative Research of America, Sarasota, FL) were placed sc in the neck of each animal According to the manufacturer's information, capsules provide continuous release of hormone at serum concentrations of 150-250 pmol/liter, in the range of physiological levels in mice during the estrous cycle This stable physiological level of estrogen promotes the growth of transplanted human endometrium and avoids intermouse differences related to various stages of the estrous cycle
- TEM Optical microscopy
- TEM transmission electron microscopy
- morphometry was performed to ascertain the presence of endometrial glands and stroma and study subcellular ultrastructural changes, area of the implants and cellular density
- TaqMan Real-time PCR and 2 ⁇ CI methods were used to analyze the gene expression profiles of three different markers that promote angiogenesis (VEGF, VEGFR-2, Notch-4), Ang ⁇ opo ⁇ et ⁇ n-1 (Ang-1 ), an antiangiogenesis marker which promotes the enlargement of existing vessels and resistance to leakage, and Wnt-1 Demonstration of the presence of the VEGF and dopamine type 2 receptor (Dp-r2) expression in experimental implants, human peritoneal endometriotic lesions, and endometrium, was conducted using the TaqMan Realtime PCR and 2 ⁇ CI method (Fig 6a, 6b) Similarly, this method was used to demonstrate the presence of VEGFR-2 expression in human peritoneal endometriotic lesions, and endometrium (Fig 6b)
- the animals treated with cabergoline both low and high dose groups
- treatment with cabergoline appears to reduce the number of active endometriotic lesions in this model
- the OM and TEM studies showed that in the control group the endometriotic lesions presented a high cellular stroma and a histological aspect of complete reorganization and structure, as may be seen in a typical human endometriosis lesion
- treated lesions high and low dose of cabergoline
- Figure 2 shows the blood vessels (mm 3 ) for the control, low and high dosage groups, divided between "mature” blood vessels and "newly formed” blood vessels
- the control group has a greater proportion of newly formed blood vessels (indicative of significant angiogenesis), while the low and high dose groups have a significantly greater proportion of mature blood vessels, suggestive of significantly reduced angiogenesis This was also demonstrated by histology (results not shown) These results indicate that the cabergoline significantly reduced new blood vessel formation (angiogenisis), in this model
- Figure 3 shows the percentage of blood vessels in the control and low and high dosage groups
- the control group has approximately 74% of the total blood vessels as newly formed blood vessels, indicating significant angiogenisis
- the low and high dosage groups on the other hand, have approximately 85 to 89% of the total as mature blood vessels, indicating that angiogenisis is not significant
- Figure 4 shows the results of a proliferation study
- An immunocyto chemistry study using the K ⁇ -67 antibody ( ⁇ e analysing the degree of cellular proliferation employing antibodies against K ⁇ -67) was used to evaluate the proliferative activity of the implants using methods known in the art
- Image counting software was used to count the K ⁇ -67 positive cells and hence calculate the proliferation index in each group
- a significant (P ⁇ 0 001) decrease in proliferation was observed in lesions in animals treated with cabergoline (both low and high dose groups) compared with the control group
- angiogenic status of the lesions was initially analyzed using immunofluorescence employing antibodies to identify new (vWF+/ ⁇ SMA-) and old vessels (vWF+/ ⁇ SMA+) and confocal microscopy (Leica Confocal Software) Immunofluorescence employing antibodies raised against the Von Willebrand factor (vWF) present in endothelial cells and vascular smooth muscle cells ( ⁇ - SMA) can be used to test the antiangiogenic action Cb2 Blood vessel which are not of new formation, are rounded by a smooth muscle layer which confers maturity to them Identification of endothelial cells was made employing vWF, whereas mature vessels were identified by ⁇ -SMA positive staining Thus, vWF+ / ⁇ SMA- blood vessels were considered new or immature, while vWF+ / ⁇ SMA+ vessels were classified as old or mature blood vessels
- TaqMan Real-time PCR and 2 ⁇ °' methods were used to analyze the gene expression profiles of three different markers that promote angiogenesis (VEGF, VEGFR-2, Notch-4), Ang ⁇ opo ⁇ et ⁇ n-1 (Ang-1), an antiangiogenesis marker which promotes the enlargement of existing vessels and resistance to leakage, and Wnt-1
- the housekeeping 18S rRNA was used to normalize the target gene Ct values
- the Ct value in each group was expressed relative to the control group Ct values (calibrator), to calculate the relative expression by the 2 ⁇ CI method cDNA obtained from sarcoma 180 tumor cells (S-180) and human umbilical vein endothelial cells (HUVEC) was used as negative and positive control, respectively, for the VEGF and VEGFR-2 gene expression
- Spleen was used as positive control for Ang-1 and Wnt-1
- lung was employed as a Notch-4 positive control
- Table 1 shows that the gene expression profiles of pro-angiogenic markers (VE
- HUVEC and S-180 cDNA cells were 10 HUVEC and S-180 cDNA cells, respectively.
- control Ct values were used as a calibrator, and in human peritoneal lesions the HUVEC Ct values were employed as calibrator to calculate the relative expression by 2 " ⁇ CI method.
- Figure 6a shows the presence of VEGF and Dp-r2 in endometrial implants of the animals in the three established groups. There was a trend
- FIG. 6b shows (left-hand column) the relative expression of VEGF, VEGFR-2 (KDR) and D2R ("Dp-r2") in different types of endomet ⁇ otic lesions, red, white and black
- Dp-r2 D2R
- VEGF, VEGFR-2 (KDR) and D2R in the endometrium
- KDR KDR
- D2R D2R
- results indicate that administration of dopamine agonists has a significant effect on endometriosis, possibly linked to action on angiogenesis
- results may be related to the presence of dopamine receptors in eutopic and ectopic endometrial tissue
- a formulation as a tablet for oral use is 0 5 mg of cabergoline
- Example A A patient undergoes diagnostic laparoscopy after suffering chronic pelvic pain and is diagnosed with endometriosis type III At the same laparoscopy, the patient undergoes surgery such as resection of available lesions and administration of cabergoline is initiated
- Example B Patient diagnosed previously of endometriosis, presenting with symptoms of pelvic pain and dysmenorrhea Administration of cabergoline is initiated without surgery
- Example C Patient diagnosed with endometriosis undergoing treatment with GnRH agonists (or danazol or aromatase inhibitors) and administration of cabergoline is initiated (with continued use of GnRH agonist) for a period After a further 3 or 6 months of no therapy, patient restarts cabergoline for a further period
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08751001A EP2109449B1 (en) | 2007-02-01 | 2008-02-01 | Medicament for the treatment of endometriosis |
CA2676910A CA2676910C (en) | 2007-02-01 | 2008-02-01 | Medicament for the treatment of endometriosis |
AT08751001T ATE516805T1 (en) | 2007-02-01 | 2008-02-01 | MEDICINE FOR TREATING ENDOMETRIOSIS |
PL08751001T PL2109449T3 (en) | 2007-02-01 | 2008-02-01 | Medicament for the treatment of endometriosis |
SI200830385T SI2109449T1 (en) | 2007-02-01 | 2008-02-01 | Medicament for the treatment of endometriosis |
DK08751001.2T DK2109449T3 (en) | 2007-02-01 | 2008-02-01 | Drug for the treatment of endometriosis |
CN2008800038285A CN101641098B (en) | 2007-02-01 | 2008-02-01 | medicament for the treatment of endometriosis |
AU2008211633A AU2008211633B2 (en) | 2007-02-01 | 2008-02-01 | Medicament for the treatment of endometriosis |
KR1020097017899A KR101160225B1 (en) | 2007-02-01 | 2008-02-01 | Medicament for the treatment of endometriosis |
NZ578569A NZ578569A (en) | 2007-02-01 | 2008-02-01 | Medicament for the treatment of endometriosis using dopamine agonists cabergoline or quinagolide |
US12/525,342 US8927568B2 (en) | 2007-02-01 | 2008-02-01 | Medicament for the treatment of endometriosis |
MX2009008191A MX2009008191A (en) | 2007-02-01 | 2008-02-01 | Medicament for the treatment of endometriosis. |
JP2009547780A JP5211073B2 (en) | 2007-02-01 | 2008-02-01 | Drugs for the treatment of endometriosis |
BRPI0806944-1A2A BRPI0806944A2 (en) | 2007-02-01 | 2008-02-01 | ENDOMETRIOSIS TREATMENT MEDICINE |
IL200032A IL200032A (en) | 2007-02-01 | 2009-07-23 | Dopamine agonist for use in the treatment or prevention of endometriosis |
HK10103367.7A HK1134911A1 (en) | 2007-02-01 | 2010-04-01 | Medicament for the treatment of endometriosis |
US14/543,478 US9023862B2 (en) | 2007-02-01 | 2014-11-17 | Medicament for the treatment of endometriosis |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07250429.3 | 2007-02-01 | ||
EP07250429A EP1952813A1 (en) | 2007-02-01 | 2007-02-01 | Medicament for the treatment of endometriosis |
US94716507P | 2007-06-29 | 2007-06-29 | |
US60/947,165 | 2007-06-29 | ||
GB0712626.1 | 2007-06-29 | ||
GB0712626A GB2450533A (en) | 2007-06-29 | 2007-06-29 | Treatment and prevention of endometriosis using dopamine agonists. |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/525,342 A-371-Of-International US8927568B2 (en) | 2007-02-01 | 2008-02-01 | Medicament for the treatment of endometriosis |
US14/543,478 Continuation US9023862B2 (en) | 2007-02-01 | 2014-11-17 | Medicament for the treatment of endometriosis |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008093247A2 true WO2008093247A2 (en) | 2008-08-07 |
WO2008093247A3 WO2008093247A3 (en) | 2008-12-04 |
Family
ID=39674574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2008/001273 WO2008093247A2 (en) | 2007-02-01 | 2008-02-01 | Medicament for the treatment of endometriosis |
Country Status (21)
Country | Link |
---|---|
US (2) | US8927568B2 (en) |
EP (1) | EP2109449B1 (en) |
JP (1) | JP5211073B2 (en) |
AR (1) | AR065139A1 (en) |
AT (1) | ATE516805T1 (en) |
AU (1) | AU2008211633B2 (en) |
BR (1) | BRPI0806944A2 (en) |
CA (1) | CA2676910C (en) |
DK (1) | DK2109449T3 (en) |
HK (1) | HK1134911A1 (en) |
IL (1) | IL200032A (en) |
JO (1) | JO2730B1 (en) |
MX (1) | MX2009008191A (en) |
NZ (1) | NZ578569A (en) |
PL (1) | PL2109449T3 (en) |
PT (1) | PT2109449E (en) |
RU (1) | RU2423146C2 (en) |
SA (1) | SA08290041B1 (en) |
SI (1) | SI2109449T1 (en) |
TW (1) | TWI411436B (en) |
WO (1) | WO2008093247A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010150098A3 (en) * | 2009-06-26 | 2011-05-12 | Ferring International Center Sa | Use of quingolide in the treatment of endometriosis, pain and cancer |
WO2023031218A1 (en) * | 2021-08-31 | 2023-03-09 | Ferring B.V. | Diagnosis and treatment of ectopic endometriosis |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3017809A1 (en) | 2014-11-07 | 2016-05-11 | Ferring B.V. | Drug-device unit containing quinagolide |
US20200315996A1 (en) * | 2016-06-02 | 2020-10-08 | Board Of Trustees, Southern Illinois University | Treatment of Endometriosis and Niclosamide Derivatives |
WO2018221562A1 (en) * | 2017-05-30 | 2018-12-06 | 有限会社イムノ | Composition for inhibiting production of il-8 from activated t cell |
RU2732251C1 (en) * | 2019-11-29 | 2020-09-14 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" | Method of treating external genital endometriosis |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993003752A1 (en) * | 1991-08-19 | 1993-03-04 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Decapeptide having dopamine stimulating activity |
US6359130B1 (en) * | 1998-06-05 | 2002-03-19 | Cephalon, Inc. | Bridged indenopyrrolocarbazoles |
WO2006117608A1 (en) * | 2005-04-29 | 2006-11-09 | Ferring International Center S.A. | Treatment or prevention of ovarian hyperstimulation syndrome (ohss) using a dopamine agonist |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0208417A3 (en) | 1985-06-12 | 1989-09-06 | SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu | Use of 1-(8-alpha-ergolinyl)-3,3-diethyl urea derivatives in the treatment of endometritis |
US6572879B1 (en) | 1995-06-07 | 2003-06-03 | Alza Corporation | Formulations for transdermal delivery of pergolide |
RU2273481C2 (en) * | 2004-05-27 | 2006-04-10 | Варвара Анатольевна Волкова | Method for enhancing effectiveness of infertility treatment caused by small-scale external genital endometriosis |
WO2010150098A2 (en) | 2009-06-26 | 2010-12-29 | Ferring International Center Sa | Treatment of endometriosis |
-
2008
- 2008-01-30 SA SA08290041A patent/SA08290041B1/en unknown
- 2008-02-01 JP JP2009547780A patent/JP5211073B2/en active Active
- 2008-02-01 CA CA2676910A patent/CA2676910C/en active Active
- 2008-02-01 AR ARP080100431A patent/AR065139A1/en not_active Application Discontinuation
- 2008-02-01 EP EP08751001A patent/EP2109449B1/en active Active
- 2008-02-01 BR BRPI0806944-1A2A patent/BRPI0806944A2/en not_active Application Discontinuation
- 2008-02-01 TW TW097103971A patent/TWI411436B/en active
- 2008-02-01 DK DK08751001.2T patent/DK2109449T3/en active
- 2008-02-01 PT PT08751001T patent/PT2109449E/en unknown
- 2008-02-01 AU AU2008211633A patent/AU2008211633B2/en active Active
- 2008-02-01 AT AT08751001T patent/ATE516805T1/en active
- 2008-02-01 NZ NZ578569A patent/NZ578569A/en unknown
- 2008-02-01 RU RU2009129252/15A patent/RU2423146C2/en active
- 2008-02-01 SI SI200830385T patent/SI2109449T1/en unknown
- 2008-02-01 WO PCT/IB2008/001273 patent/WO2008093247A2/en active Application Filing
- 2008-02-01 MX MX2009008191A patent/MX2009008191A/en active IP Right Grant
- 2008-02-01 PL PL08751001T patent/PL2109449T3/en unknown
- 2008-02-01 US US12/525,342 patent/US8927568B2/en active Active
- 2008-02-02 JO JO200833A patent/JO2730B1/en active
-
2009
- 2009-07-23 IL IL200032A patent/IL200032A/en active IP Right Grant
-
2010
- 2010-04-01 HK HK10103367.7A patent/HK1134911A1/en unknown
-
2014
- 2014-11-17 US US14/543,478 patent/US9023862B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993003752A1 (en) * | 1991-08-19 | 1993-03-04 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Decapeptide having dopamine stimulating activity |
US6359130B1 (en) * | 1998-06-05 | 2002-03-19 | Cephalon, Inc. | Bridged indenopyrrolocarbazoles |
WO2006117608A1 (en) * | 2005-04-29 | 2006-11-09 | Ferring International Center S.A. | Treatment or prevention of ovarian hyperstimulation syndrome (ohss) using a dopamine agonist |
Non-Patent Citations (6)
Title |
---|
CARPENTER ET AL: "A systematic review to determine the effectiveness of medical therapies at causing disease regression in endometriosis" REVIEWS IN GYNAECOLOGICAL AND PERINATAL PRACTICE, ELSEVIER, KIDLINGTON, GB, vol. 6, no. 3-4, September 2006 (2006-09), pages 161-167, XP005625236 ISSN: 1871-2320 * |
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CHERNOV, YU. N. ET AL: "Method for enhancing effectiveness of infertility treatment caused by small-scale external genital endometriosis" XP002443562 retrieved from STN Database accession no. 2006:332641 & RU 2 273 481 C2 (RUSSIA) 10 April 2006 (2006-04-10) * |
M.H. BEERS ET AL.: "The Merck index" 1999, MERCK , XP002497582 See pages 1956-1959: "Endometriosis" * |
NOVELLA-MAESTRE E ET AL: "Antiangiogenic action of dopamine agonists in experimentally-induced endometriotic lesions" HUMAN REPRODUCTION (OXFORD), vol. 22, no. Suppl. 1, July 2007 (2007-07), page I47, XP002497581 & 23RD ANNUAL MEETING OF THE EUROPEAN-SOCIETY-OF-HUMAN-REPRODUCTION-AND EMBRYOLOGY; LYON, FRANCE; JULY 01 -04, 2007 ISSN: 0268-1161 * |
SCHMIDT C L: "Endometriosis: a reappraisal of pathogenesis and treatment." FERTILITY AND STERILITY AUG 1985, vol. 44, no. 2, August 1985 (1985-08), pages 157-173, XP009086932 ISSN: 0015-0282 * |
TSAKOK F H ET AL: "The use of bromocriptine in hyperprolactinemia and galactorrhea in Singapore." INTERNATIONAL JOURNAL OF GYNAECOLOGY AND OBSTETRICS: THE OFFICIAL ORGAN OF THE INTERNATIONAL FEDERATION OF GYNAECOLOGY AND OBSTETRICS APR 1985, vol. 23, no. 2, April 1985 (1985-04), pages 109-113, XP002443515 ISSN: 0020-7292 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010150098A3 (en) * | 2009-06-26 | 2011-05-12 | Ferring International Center Sa | Use of quingolide in the treatment of endometriosis, pain and cancer |
JP2012530776A (en) * | 2009-06-26 | 2012-12-06 | フェリング ベスローテン フェンノートシャップ | Treatment of endometriosis |
WO2023031218A1 (en) * | 2021-08-31 | 2023-03-09 | Ferring B.V. | Diagnosis and treatment of ectopic endometriosis |
Also Published As
Publication number | Publication date |
---|---|
IL200032A0 (en) | 2010-04-15 |
RU2423146C2 (en) | 2011-07-10 |
BRPI0806944A2 (en) | 2014-05-06 |
US9023862B2 (en) | 2015-05-05 |
SI2109449T1 (en) | 2011-11-30 |
ATE516805T1 (en) | 2011-08-15 |
EP2109449B1 (en) | 2011-07-20 |
WO2008093247A3 (en) | 2008-12-04 |
AU2008211633A1 (en) | 2008-08-07 |
HK1134911A1 (en) | 2010-05-20 |
US20100113499A1 (en) | 2010-05-06 |
RU2009129252A (en) | 2011-03-10 |
AR065139A1 (en) | 2009-05-20 |
NZ578569A (en) | 2011-08-26 |
JP2010517992A (en) | 2010-05-27 |
TW200845989A (en) | 2008-12-01 |
US8927568B2 (en) | 2015-01-06 |
AU2008211633B2 (en) | 2011-04-21 |
DK2109449T3 (en) | 2011-09-12 |
MX2009008191A (en) | 2009-08-12 |
IL200032A (en) | 2015-06-30 |
JP5211073B2 (en) | 2013-06-12 |
CA2676910A1 (en) | 2008-08-07 |
PL2109449T3 (en) | 2011-12-30 |
EP2109449A2 (en) | 2009-10-21 |
SA08290041B1 (en) | 2012-06-05 |
TWI411436B (en) | 2013-10-11 |
CA2676910C (en) | 2012-01-03 |
JO2730B1 (en) | 2013-09-15 |
PT2109449E (en) | 2011-11-02 |
US20150073010A1 (en) | 2015-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9023862B2 (en) | Medicament for the treatment of endometriosis | |
Eshghpour et al. | Effect of menstrual cycle on frequency of alveolar osteitis in women undergoing surgical removal of mandibular third molar: a single-blind randomized clinical trial | |
Efstathiou et al. | Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model | |
US20220152053A1 (en) | Methods and compositions for treating various disorders | |
Ferrero et al. | Three-month treatment with ulipristal acetate prior to laparoscopic myomectomy of large uterine myomas: a retrospective study | |
CN103037862A (en) | Methods of treating or preventing estrogen-related diseases | |
CN112020360A (en) | Compounds and their use in alleviating symptoms associated with menopause | |
Harada et al. | SR-16234, a novel selective estrogen receptor modulator for pain symptoms with endometriosis: an open-label clinical trial | |
EP1952813A1 (en) | Medicament for the treatment of endometriosis | |
JP5968781B2 (en) | Treatment of endometriosis | |
GB2450533A (en) | Treatment and prevention of endometriosis using dopamine agonists. | |
KR101160225B1 (en) | Medicament for the treatment of endometriosis | |
RU2798675C1 (en) | Method of prevention of postoperative complications of penetrating keratoplasty | |
Zegarelli et al. | Oral pathology affecting older adults | |
Arefi et al. | Laparoscopic Ovarian Drilling in Metformin and Clomiphene Resistant Women with Polycystic Ovarian Syndrome | |
JP2007529476A (en) | Use of 5-HT3 receptor antagonist in the manufacture of a medicament for the treatment of painful abdominal diseases derived from non-gastrointestinal tract | |
SALEH et al. | The upper respiratory tract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880003828.5 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 578569 Country of ref document: NZ Ref document number: 2008751001 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200032 Country of ref document: IL Ref document number: 2008211633 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2676910 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2009547780 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/008191 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009081159 Country of ref document: EG |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2008211633 Country of ref document: AU Date of ref document: 20080201 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5265/DELNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2009000495 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097017899 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009129252 Country of ref document: RU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08751001 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12525342 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0806944 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090731 |